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Abstract
Introduction: Metabolic bone disease represents a major cause of morbidity in patients with thalassaemia major. The aim of our study 
was to assess the prevalence and underlying contributory factors of osteopenia/osteoporosis in a randomly selected population of adult 
patients with thalassaemia major.
Patients and methods: The study population was selected using the random sampling method from the patients’ database of our thalas-
saemia clinic. Only transfusion-dependent beta-thalassaemia patients aged over 17 and with no history of treatment with bisphosphonates 
were included. BMD of lumbar spine and right femoral neck were measured by means of the calibrated dual energy X-ray absorption 
method. Independent factors likely to be associated with low bone mass were determined and included in the analysis to ascertain pos-
sible associations.
Results: Our study included 40 patients (19 female and 21 male; mean age: 23.0 ± 4.1). The mean Z score of the right femoral neck was 
–1.2 (95% CI: –0.9 to –1.5) and for lumbar spine was –2.1 (95% CI: –1.7 to –2.5). The prevalences of osteopenia and osteoporosis involving 
the right femoral neck were 37.5%, and 12.5%, respectively. The respective prevalence rates for lumbar spine were 47.5% and 37.5%. Our 
study showed patient’s weight, age, duration of the disease and history of hypogonadism or concurrent hypothyroidism are significant 
contributory factors or predictors of bone mineral loss.
Conclusions: Regarding the high prevalence of osteopenia/osteoporosis in patients with thalassaemia major, all patients should be screened 
periodically for bone disease. The uncertainty and disagreements as to the possible role of different factors indicate the necessity for 
further studies in order to recognise the pathophysiologic fundamentals of this serious complication of thalassaemia major. (Endokrynol 
Pol 2012; 63 (4): 264–269)
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Streszczenie
Wstęp: Zaburzenia metabolizmu tkanki kostnej są główna przyczyną chorobowości u pacjentów z talasemią major. Celem niniejszego 
badania była ocena częstości osteopenii/osteoporozy i określenie czynników przyczyniających się do ich rozwoju w losowo wybranej 
grupie chorych na talasemię major.
Pacjenci i metody: Uczestników badania wybrano losowo z bazy danych pacjentów poradni leczenia talasemii. Do analizy włączono jedy-
nie chorych w wieku powyżej 17 lat z transfuzjozależną talasemią beta, nieleczonych wcześniej bisfosfonianami. Metodą absorpcjometrii 
podwójnej wiązki promieniowania rentgenowskiego zmierzono BMD odcinka lędźwiowego kręgosłupa i szyjki prawej kości biodrowej. 
Określono niezależne czynniki, które mogły wpływać na niską masę kostną i uwzględniono je w analizie, aby wykryć wszelkie możliwe 
związki.
Wyniki: Do badania włączono 40 chorych (19 kobiet i 21 mężczyzn, średnia wieku 23,0 ± 4,1 roku). Średnie wartości Z score wynosiły 
–1,2 (95% CI: od –0,9 do –1,5) dla szyjki prawej kości biodrowej i –2,1 (95% CI: od –1,7 do –2,5) dla kręgosłupa lędźwiowego. Częstość 
osteopenii i osteoporozy, oceniana na podstawie gęstości mineralnej szyjki prawej kości udowej, wynosiła odpowiednio 37,5%, i 12,5%. 
W badaniu wykazano, że masa ciała, wiek, czas trwania choroby i hipogonadyzm w wywiadzie lub współistniejąca niedoczynność tarczycy 
są istotnymi czynnikami ryzyka lub predyktorami utraty minerału kostnego.
Wnioski: W związku z częstym występowaniem osteopenii/osteoporozy u wszystkich chorych na talasemię major należy okresowo prze-
prowadzać badania w kierunku chorób kości. Wątpliwości i rozbieżne opinie na temat potencjalnej roli różnych czynników w rozwoju 
tych poważnych powikłań talasemii major wskazują na konieczność prowadzenia dalszych badań w celu poznania ich patofizjologii. 
(Endokrynol Pol 2012; 63 (4): 264–269)
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Introduction
Thalassaemia major, as a chronic haematologic disor-
der, leads to altered bone metabolism, which is due 
to imbalanced osteoclastic bone resorption versus 
constructive osteoblastic activities [1]. Furthermore, 
the disease causes chronic anaemia and tissue hypoxia 
that disturb normal growth and puberty, also resulting 
in gonadal dysfunction. These underlying problems 
also lead to smaller bone size [1] and abnormal bone 
formation [2], both of which may partly contribute to 
decreased bone mineral density (BMD) in patients with 
thalassaemia. The presence of diabetes mellitus and 
hypothyroidism, the parathyroid gland dysfunction, the 
accelerated haematopoiesis with progressive bone mar-
row expansion, the direct iron toxicity on osteoblasts, 
the effects of iron chelating agents, the deficiency of 
growth hormone or insulin like growth factors, and 
genetic factors all have been proposed as other causes 
of osteopenia and osteoporosis in thalassaemic patients 
[3–9]. Hence, numerous explanations have been sug-
gested for the unpleasant process of bone mineral loss 
in thalassaemia major.
Metabolic bone disease represents a major cause 
of morbidity in patients with thalassaemia major [5, 10– 
–13]. Elucidating the underlying pathogenic mecha-
nisms of bone mineral loss in thalassaemia (which are 
not yet fully understood) is urgently needed, as it will 
allow the design of optimal therapeutic and preventive 
measures for these patients [10, 14]. However, significant 
discrepancies among published reports concerning the 
underlying pathophysiologic contributors of bone min-
eral loss have resulted in inconsistencies of preventive 
and therapeutic measures among children, adolescents 
and adults with thalassaemia major.
The aim of our study was to assess the prevalence 
and underlying contributory factors of osteopenia/os-
teoporosis in a randomly selected population of adult 
patients with thalassaemia major.
Patients and methods
The study population was selected using the random 
sampling method from the patients’ database of the thalas-
saemia clinic at our hospital. Only transfusion-dependent 
beta-thalassaemia patients older than 17 were included 
in the study. All patients were on the standard treatment 
protocol for thalassaemia at the thalassaemia clinic of the 
hospital. None of the patients had a history of treatment 
with bisphosphonates. Informed consent was obtained 
from all participants prior to inclusion in the investigation. 
The study was conducted following the approval of the 
ethical committee at Tehran University of Medical Sciences 
in keeping with the guidelines of Helsinki.
Medical history by interview and review of medical 
records and physical examinations were performed. 
Demographic and anthropometric data and history 
of all treatments, as well as menstrual and pubertal 
histories, were collected. Independent factors likely 
to be associated with low bone mass (i.e. age, gender, 
history of gonadal or pubertal dysfunction, history of 
bone fracture in first degree relatives, history of iron 
chelating therapy, history of treatment with calcium and 
vitamin D, pre-transfusion haemoglobin level, serum 
levels of calcium, phosphorus, alkaline phosphatase, 
and thyroid function indices (T3, T4 and TSH)) were 
determined and included in the analysis to ascertain 
possible associations.
The assessment of BMD was carried out by means 
of the calibrated dual energy X-ray absorption (LEXX- 
-OS-DMS, France) method. BMD of lumbar spine (L1–L4) 
and right femoral neck were measured. The BMD values 
are expressed as mean values (g/cm2) ± SD. Z-score, 
which is the number of SD above or below the average 
of age- and sex-matched control subjects’ BMD, was cal-
culated. Based on the World Health Organisation defini-
tion, a Z-score of less than –2.5 SDs below the mean in 
relation to the patient’s age was defined as osteoporosis, 
and between –1.0 and –2.5 SDs as osteopenia.
The student T test and ANOVA were used to analyse 
the significance of the differences between the quantita-
tive and the qualitative variables. Also, Chi square (X2) 
statistic and Fischer exact test were used to compare 
distributions of categorical variables. A p value of < 0.05 
was considered statistically significant. All statistical 
analyses were conducted using SPSS version 13 (SPSS 
Inc., Chicago, IL, USA).
Results
Our study population included 40 patients (19 female 
and 21 male; mean age: 23.0 ± 4.1, range 17–30 years) 
with major beta-thalassaemia. Patients’ characteristics 
are summarised in Table I.
Table I. Patients’ clinical characteristics
Tabela I. Charakterystyka kliniczna badanych
Clinical characteristic Mean ± SD (range)
Age 23.0 ± 4.1 (17–30)
Height 156.5 ± 8.6 (137.0–170.0)
Weight 50.9 ± 7.0 (38.0–66.0)
Haemoglobin 9.4 ± 1.6 (6.5–12.0)
Serum calcium 7.8 ± 0.6 (6.8–8.9)
Serum phosphorus 4.6 ± 0.7 (3.3–5.7)
Serum alkaline phosphatase 119.0 ± 48.4 (58.0–210.0)
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The mean Z score of the right femoral neck was –1.2 
(95%CI: –0.9 to –1.5) and the same figure for lumbar 
spine was –2.1 (95% CI: –1.7 to –2.5). The prevalences of 
osteopenia and osteoporosis involving the right femoral 
neck were 37.5%, and 12.5%, respectively. The respec-
tive prevalence rates for lumbar spine were 47.5% and 
37.5%. All patients with abnormal right femoral neck 
BMD showed abnormally low spinal BMD.
Regarding the prevalence of abnormal BMD, there 
was no significant difference between males and fe-
males (p value = 0.8). The patients’ weight and height 
showed significant associations with BMD values of 
both hip and lumbar spine (all p values < 0.01). There 
was a significant decrease in the BMD with increasing 
patient age (Fig. 1, p value < 0.001). All patients older 
than 25 years suffered from osteoporosis. Based on the 
regression analysis, BMD of the right femoral neck could 
be calculated using the following formula: BMD of 
the right femoral neck = 1.40 – 0.023 × patient,s age. 
Similar formulas can be generated using height: BMD 
of the right femoral neck = –0.84 + 0.01 × patient’s 
age height [cm] and weight BMD of the right femoral 
neck = 0.40 + 0.01 × patient’s age weight [kg], as the 
independent variables.
We found a significant relationship between 
pre-transfusion haemoglobin level and lumbar spine 
BMD Z score (p < 0.01), while there was not such an as-
sociation between pre-transfusion haemoglobin level 
and right femoral neck BMD Z score (p = 0.1). There was 
no significant correlation between serum concentrations 
of calcium, phosphorus, and alkaline phosphatase and 
BMD of hips and spines (all p values more than 0.1). 
Although there was no significant correlation between 
recent serum concentrations of Thyroxin (T4), Thyro-
nine (T3), and Thyroid Stimulating Hormone (TSH), 
a history of hypothyroidism (as depicted by current 
treatment with thyroid hormones) showed significant 
association with bone mineral loss in both hip and spine 
(both p values < 0.01): BMD Z score at the right femo-
ral head in patients with a history of hypothyroidism 
was –1.6 compared to –1.1 in patients with no history 
of hypothyroidism. Although there was no significant 
correlation between recent serum concentrations of 
testosterone, oestradiol, luteinising hormone (LH), and 
follicle stimulating hormone (FSH), as illustrated by 
Figure 2, there was a significant relationship between 
bone mineral loss and history of gonadal dysfunction 
(as depicted by current or past treatment with related 
hormones) or impaired puberty (p = 0.01).
Eleven patients were treated using desferrioxam-
ine regularly, 18 patients received desferrioxamine 
irregularly/intermittently, and 11 patients stated that 
they had discontinued receiving desferrioxamine 
for more than six months. There was no association 
between the frequency and regularity of treatment 
with iron chelating agent and BMD (p values > 0.2). 
Similarly, there was no relationship between a family 
history of bone fracture in first degree relatives and 
BMD (p values > 0.2). In our population, 42.5% of 
the patients were receiving calcium and vitamin D 
supplementations. However, calcium and vitamin D 
Figure 1. Association between patients’ age and bone mineral 
density (BMD)
Rycina 1. Zależności między wiekiem chorych a gęstością mineralną 
kości (BMD)
Figure 2. Significant association between bone mineral loss and 
history of gonadal dysfunction or impaired puberty; BMD — bone 
mineral density
Rycina 2. Istotne zależności między utratą minerału kostnego a 
dysfunkcją gonad i zaburzeniami dojrzewania płciowego; BMD 
— gęstość mineralna kości
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supplementations showed no significant association 
with BMD values (p values > 0.2).
Discussion
Osteopenia and osteoporosis are the commonest bone com-
plications of beta-thalassaemia, despite regular transfusions 
and iron chelation therapy [6, 11, 12, 15, 16]. At least half of 
our thalassaemics suffered from some degree of bone mineral 
loss. Hence, impairment of bone mineral density in Iranian 
thalassaemics even on proper treatment is severe and preva-
lent, as was expected. Similar or more severe figures have 
been reported by others [6, 11, 13, 14, 17]. Therefore, bone 
densitometry should be included in the periodical evaluation 
of patients with thalassaemia in order to help guide proper 
treatment in appropriate time [18].
The aetiology of thalassaemia major-induced bone 
mineral loss is multi-factorial and complicated [14, 19], 
and, as our study showed, a patient’s weight, age, du-
ration of the disease and history of hypogonadism or 
concurrent hypothyroidism are significant contributory 
factors or predictors. These findings are confirmed by 
similar previous reports [15].
Site of bone mineral loss
In our study, Z-score of BMD at the lumbar spine was 
significantly lower than at the femoral neck. All previous 
reports agree that bone mineral loss is more severe in the 
spinal column compared to the femoral neck [6, 11, 14, 17, 
28–30]. The explanation of this differential bone mineral 
loss can be the accelerated haematopoiesis with progres-
sive bone marrow expansion, a process which involves the 
spine more severely than the proximal femurs.
Patient’s age
Normally, peak bone mass is attained shortly after 
completion of puberty and is stable until the third 
decade of life [13, 10]. It is just after the age of 30 that 
age-related bone mineral loss initiates [10]. However, in 
thalassaemic patients, this process starts much sooner 
and progresses more swiftly.
Based on our study findings and those of others 
[13, 20–23], BMD Z score significantly deteriorates with 
age. It is known that in those patients whose lifespan is 
getting longer, osteopenia and osteoporosis are among 
the major causes of morbidity, with a strong negative 
impact on the quality of life [11, 24].
Gender
In accordance with Chapelon et al. [2] and Shamshirsaz 
et al. [17], we found no significant association between 
BMD and gender in our post-pubertal group of pa-
tients. However, significant gender differences have 
been found by other groups [14, 25, 26].
Patient’s weight and height
In our study, a patient’s weight was a significant pre-
dictor of BMD. The same finding has been reported by 
numerous groups of investigators [11, 13, 17, 27], who 
have shown that body fat and lean mass were positive 
predictors for BMD Z-scores following adjustment for 
possible confounding factors such as transfusion status, 
age, sex, ethnicity, calcium intake, and baseline physi-
cal activity. It seems that there is a general consensus 
regarding the protective effects of maintaining normal 
body weight for BMD.
In accordance with our study findings, most prev- 
ious reports found that a patient’s weight is also a sig-
nificant predictor of BMD [13, 17, 21, 23].
Pre-transfusion haemoglobin level
In our study, femoral BMD Z score showed no re-
lationship with pre-transfusion haemoglobin level. 
The same conclusion has been made by other groups: 
the normalisation of haemoglobin levels does not 
affect the unbalanced bone turnover in thalassaemic 
patients [5, 13, 21, 25, 26]. However, this hypothesis 
has been rejected by others [7, 18, 31], who found that 
BMD is positively correlated with the haemoglobin 
level and frequency of blood transfusions. These 
discrepancies emphasise the need for future studies 
on a larger number of patients.
Calcium and vitamin D
As found by previous investigators, regular intake of 
calcium and vitamin D [2, 12, 16, 29] do not affect the 
process of bone mineral loss. However, some authors 
do not agree with such a conclusion and advise that to 
optimise BMD in thalassaemic patients, it is essential 
to ensure sufficient intake of calcium and vitamin D 
[13, 28, 32].
Iron chelating therapy
We found no association between the frequency and 
regularity of treatment with iron chelating agents and 
BMD. Similar statements have been made by others, 
emphasising that despite effective iron chelation, 
patients continue to show increased bone resorptive 
phase, resulting in seriously diminished BMD [5, 12, 
13, 21, 26]. However, numerous reports have come to 
a contrary conclusion [17, 18, 29, 33].
Endocrinopathy
Although we could not find a significant relationship 
between serum levels of steroid or thyroid hormones 
and BMD Z scores, other groups [3, 4, 9] have found 
such a relationship. The small size of our patient group 
may limit the power of the study to unveil all possible 
relationships.
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In our study, those patients with a history of hypo-
thyroidism, gonadal dysfunction or impaired puberty 
showed lower BMD values. In this line, other inves-
tigators [3, 8, 11, 14, 20, 22, 26, 29, 32, 34–37] have also 
stated that low BMD values are found more commonly 
in the background of endocrinopathies. These authors 
believe that gonadal dysfunction probably has the most 
dominant role in the pathogenesis of bone disease in 
thalassaemia major. Christoforidis et al. [33] also stated 
that management of possible endocrine complications 
is crucial in order to protect normal bone health during 
adulthood.
The anabolic effects of sex steroids in bone are es-
sential, not only for the acquisition of bone mass during 
adolescence and puberty, but also for the maintenance 
of peak bone mass during adulthood [4, 10, 38]. It has 
been emphasised that “thalassaemic patients are often 
hypogonadal and therefore the lack of sexual hor-
mones in critical periods, such as puberty, contributes 
to the failure to achieve optimal peak bone mass and 
to maintain bone mineral density later in life” [3, 10, 30, 
39, 40]. On the other hand, it has been emphasised that 
adequate hormone replacement therapy does not neces- 
sarily correct the underlying pathologic mechanisms 
leading to bone mineral loss in thalassaemic patients 
[5, 12, 13, 38].
Limitations of the study
The main limitation was the small number of patients 
studied, which reduced the power of the study to elu-
cidate some possible associations.
Conclusions
Regarding the high prevalence of osteopenia/osteopo-
rosis in patients with thalassaemia major, all patients 
should be screened periodically for bone disease. The 
uncertainty and disagreements on the possible role of 
different factors indicate the necessity of further studies 
in order to recognise the pathophysiologic fundamen-
tals of this serious complication of thalassaemia major. 
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